Clinical Trials Logo

Filter by:
NCT ID: NCT05556096 Recruiting - Clinical trials for Generalized Myasthenia Gravis

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

NCT ID: NCT05555732 Recruiting - Clinical trials for Metastatic Non Small Cell Lung Cancer

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Start date: January 11, 2023
Phase: Phase 3
Study type: Interventional

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

NCT ID: NCT05554978 Recruiting - Cardiac Arrest Clinical Trials

Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest

Beta-Arrest
Start date: March 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study investigates the efficacy of landiolol versus placebo in patients with out-of-hospital cardiac arrest (OHCA) and refractory ventricular fibrillation (electrical storm).

NCT ID: NCT05554835 Recruiting - MDS Clinical Trials

Global Registry and Natural History Study for Mitochondrial Disorders

Start date: February 1, 2009
Phase:
Study type: Observational [Patient Registry]

The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome measures and conduction of clinical trials.

NCT ID: NCT05552976 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

SUCCESSOR-2
Start date: January 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

NCT ID: NCT05551780 Recruiting - Clinical trials for Chronic Total Occlusion of Artery of the Extremities

Treatment of Calcific Total Occlusions in Peripheral Artery Disease

CaTO-PAD
Start date: February 21, 2023
Phase: N/A
Study type: Interventional

Prospective, multi-center, non-randomized, open label, clinical study intended to provide data to demonstrate safety and performance of the SoundBite Crossing System XS Peripheral.

NCT ID: NCT05549297 Recruiting - Advanced Melanoma Clinical Trials

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Start date: December 19, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma

NCT ID: NCT05545332 Recruiting - Clinical trials for Post COVID-19 Condition

Prospective Multidisciplinary Post-COVID-19 Registry Tyrol

PRECISE
Start date: March 3, 2022
Phase:
Study type: Observational

Longitudinal, prospective observational cohort study enrolling patients with persisting symptoms (> 12 weeks) after COVID-19 in a multidisciplinary care model.

NCT ID: NCT05544695 Recruiting - Clinical trials for Interstitial Cystitis and Bladder Pain Syndrome

Real-world Evidence Study on Cystistat

IC/BPS
Start date: October 21, 2022
Phase:
Study type: Observational

This study will be conducted with the aim of ensuring the continued acceptability of the benefit-risk ratio and confirming the safety and performance of the device throughout its expected lifetime. Cystistat is supplied as a 50 mL solution containing 40 mg of sodium hyaluronate. It is indicated for the temporary replacement of the GAG layer in the bladder.

NCT ID: NCT05537766 Recruiting - Clinical trials for Relapsed/Refractory Hairy Cell Leukemia

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

ZUMA-25
Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A - no longer recruiting), relapsed/refractory Richter transformation (r/r RT) (Substudy B), relapsed/refractory Burkitt lymphoma (r/r BL) (Substudy C and relapsed/refractory hairy cell leukemia (r/r HCL) (Substudy D - no longer recruiting).